Tokyo, July 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058413) titled 'Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation' on July 9.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Self control

Primary Sponsor: Institute - Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch

Condition: Condition - Skin tissue that has atrophied or changed due to aging, trauma, congenital etc. Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - This study will use a prospective survey based on patient data to examine the effectiveness of PRP treatment on skin tissue that has atrophied or been deformed due to aging, trauma, congenital conditions, etc. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - PRP is prepared using the patient's own blood as the source material. The prepared PRP is then administered to the patient's face. Injection is performed on both the right and left sides of the face as follows: Right side: PRP Left side: Normal saline The injections are performed using a mesotherapy device, with the target depth being the dermal layer. The volume of PRP administered ranges from 1 to 6 mL, depending on the size and condition of the treated area.

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Individuals who meet all of the following criteria Have clear tissue deformity or atrophy due to congenital conditions, trauma, or aging Are expected to benefit from this treatment Wish to receive the treatment and have been deemed suitable for it by a physician Are able to attend outpatient visits adults Have provided written informed consent for this treatment Key exclusion criteria - Have a clearly apparent infection in the area surrounding the injection site Have a predisposition to keloid formation Have an insufficient understanding of this treatment Lack the capacity to make an informed decision regarding this treatment Do not wish to receive this treatment or are unable to provide informed consent Are deemed inappropriate for the treatment by the physician, such as those with malignant tumors, infectious tumors, infectious diseases, or inflammatory diseases Target Size - 10

Recruitment Status: Recruitment status - Enrolling by invitation Date of protocol fixation - 2025 Year 04 Month 01 Day Date of IRB - 2025 Year 03 Month 29 Day Anticipated trial start date - 2025 Year 04 Month 15 Day Last follow-up date - 2025 Year 10 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066783

Disclaimer: Curated by HT Syndication.